The Operational Reality of Agentic AI in Phase 2–3 Trials
You heard an honest account of what is working in live programs, what is still falling short, and what clinical operations will realistically look like by 2030. This white paper takes that conversation further.
Get the white paper.
Talk to a PSI expert.
Select what’s most useful for your program – the white paper, a direct conversation, or both.
* indicates required fields
This is not a technology primer
Most AI discussions in clinical development avoid the hard question: is this actually changing outcomes? This white paper is written for sponsors who need to answer that question for their own programs.
Human-led processes bring expertise and adaptability, but also variability and delay. Agentic AI systems can coordinate and adapt at scale, but carry real limitations in context, scope, and the ability to translate insight into action.
The question for clinical development leaders isn’t whether to adopt AI. It’s whether the systems you’re deploying, and the partners you’re working with, are actually changing outcomes.
01 Where agentic AI is creating documented operational value today
Concrete evidence from live programs in site selection, startup, and real-time decision-making – not projections
02 How workforce roles are shifting as autonomous tooling matures
What this means for the teams running your trials, and where human oversight remains non-negotiable
03 What process reengineering will realistically look like by 2030
An evidence-grounded forecast for complex trial execution – not a vendor roadmap
Humans are flawed. AI is flawed. Complex phase 2–3 trials have always operated within that reality. The question isn't whether to adopt AI — it's whether the systems you're deploying are actually changing outcomes.
Delivery data you can evaluate
These aren’t benchmarks. They are measured outcomes across a portfolio of complex pivotal trials.
95%
First Patient In on time across phase 2-3 studies
97%
Last Patient In on time across phase 2-3 studies
93%
Repeat business rate from sponsor partners
Evaluating AI capabilities for a complex program?
A PSI clinical operations expert can discuss how our technology platforms and expertise apply to your specific trial design.
